Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers

Conditions

• Healthy Volunteers (Meningococcal Infection)

Interventions

• BIOLOGICAL: Meningococcal Polysaccharide (Serogroups A,C,Y and W) Tetanus Toxoid Conjugate vaccine MenACYW conjugate vaccine
• BIOLOGICAL: Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine
• BIOLOGICAL: Meningococcal Polysaccharide (serogroups A,C,Y and W-135) Diphtheria Toxoid Conjugate Vaccine
• BIOLOGICAL: Diphtheria and Tetanus Toxoids and Acellular Pertussis, inactivated Poliovirus and Haemophilus b Conjugate Vaccine
• BIOLOGICAL: Diphtheria and Tetanus Toxoids and Acellular Pertussis, Hepatitis B and Inactivated Poliovirus Vaccine
• BIOLOGICAL: Haemophilus b Conjugate Vaccine
• BIOLOGICAL: Pneumococcal 13-valent Conjugate Vaccine
• BIOLOGICAL: Rotavirus Vaccine, Live, Oral, Pentavalent
• BIOLOGICAL: Hepatitis B Vaccine
• BIOLOGICAL: Measles, Mumps, and Rubella Virus Vaccine Live
• BIOLOGICAL: Varicella Virus Vaccine Live

Sponsor

Sanofi Pasteur, a Sanofi Company